Prelude Therapeutics Incorporated (NASDAQ:PRLD) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Analyst consensus: Hold. Five brokerages rate Prelude Therapeutics an average "Hold" (1 sell, 1 hold, 3 buys) with a mean 12‑month price target of about $7.67.
• Large insider buys signal conviction. Orbimed Advisors LLC and director David P. Bonita each purchased 2,815,315 shares at $4.44 on April 21, boosting their holdings to 11,808,945 shares and contributing to insiders owning 63.9% of the stock.
• Mixed recent performance and valuation. Shares traded around $4.75 (market cap ~$299M); Q1 EPS of -$0.20 beat estimates but revenue of $5.64M missed consensus, and analysts expect -0.93 EPS for the year.

Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) has earned an average rating of "Hold" from the five brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $7.6667.

PRLD has been the topic of several research analyst reports. HC Wainwright upped their price target on shares of Prelude Therapeutics from $5.00 to $8.00 and gave the stock a "buy" rating in a report on Monday, April 27th. Citizens Jmp increased their target price on Prelude Therapeutics from $3.00 to $6.00 and gave the company a "market outperform" rating in a research note on Wednesday, March 11th. Wall Street Zen cut Prelude Therapeutics from a "buy" rating to a "hold" rating in a research note on Sunday, January 18th. Zacks Research raised Prelude Therapeutics to a "hold" rating in a research note on Tuesday, April 28th. Finally, D. Boral Capital assumed coverage on Prelude Therapeutics in a research note on Monday. They issued a "buy" rating and a $9.00 target price on the stock.

Insiders Place Their Bets

In other news, Director Orbimed Advisors Llc bought 2,815,315 shares of Prelude Therapeutics stock in a transaction that occurred on Tuesday, April 21st. The shares were acquired at an average price of $4.44 per share, with a total value of $12,499,998.60. Following the completion of the purchase, the director directly owned 11,808,945 shares in the company, valued at $52,431,715.80. The trade was a 31.30% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director David P. Bonita bought 2,815,315 shares of Prelude Therapeutics stock in a transaction that occurred on Tuesday, April 21st. The stock was purchased at an average cost of $4.44 per share, for a total transaction of $12,499,998.60. Following the purchase, the director owned 11,808,945 shares of the company's stock, valued at $52,431,715.80. The trade was a 31.30% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 63.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Prelude Therapeutics by 25.4% in the fourth quarter. Geode Capital Management LLC now owns 272,886 shares of the company's stock valued at $792,000 after acquiring an additional 55,318 shares during the last quarter. Acadian Asset Management LLC boosted its position in Prelude Therapeutics by 9.1% during the first quarter. Acadian Asset Management LLC now owns 529,327 shares of the company's stock valued at $405,000 after buying an additional 43,946 shares during the period. Sphera Funds Management LTD. purchased a new stake in Prelude Therapeutics during the fourth quarter valued at about $356,000. Goldman Sachs Group Inc. boosted its position in Prelude Therapeutics by 48.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 117,477 shares of the company's stock valued at $341,000 after buying an additional 38,150 shares during the period. Finally, Jane Street Group LLC boosted its position in Prelude Therapeutics by 218.9% during the fourth quarter. Jane Street Group LLC now owns 111,040 shares of the company's stock valued at $322,000 after buying an additional 76,218 shares during the period. Institutional investors own 79.72% of the company's stock.

Prelude Therapeutics Trading Up 1.0%

Shares of Prelude Therapeutics stock traded up $0.05 during trading on Monday, hitting $4.75. The stock had a trading volume of 58,571 shares, compared to its average volume of 387,943. The firm has a market cap of $299.19 million, a price-to-earnings ratio of -3.65 and a beta of 1.11. Prelude Therapeutics has a 12 month low of $0.73 and a 12 month high of $5.54. The business's 50-day moving average is $3.65 and its 200 day moving average is $2.54.

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) last released its quarterly earnings results on Tuesday, March 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.13. The firm had revenue of $5.64 million during the quarter, compared to the consensus estimate of $20.50 million. As a group, equities analysts expect that Prelude Therapeutics will post -0.93 EPS for the current year.

About Prelude Therapeutics

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude's pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude's lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.